Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The effects of concurrent human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection on mortality and patient attrition in those undergoing antiretroviral therapy continue to be a contested area of research. WHAT IS ADDED BY THIS REPORT? According to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, He, Zhu, Qiuying, Huang, Jinghua, Wu, Xiuling, Li, Bo, Liu, Xuanhua, Meng, Qin, Tang, Shuai, Lan, Guanghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652092/
https://www.ncbi.nlm.nih.gov/pubmed/38023393
http://dx.doi.org/10.46234/ccdcw2023.183
_version_ 1785136134717702144
author Jiang, He
Zhu, Qiuying
Huang, Jinghua
Wu, Xiuling
Li, Bo
Liu, Xuanhua
Meng, Qin
Tang, Shuai
Lan, Guanghua
author_facet Jiang, He
Zhu, Qiuying
Huang, Jinghua
Wu, Xiuling
Li, Bo
Liu, Xuanhua
Meng, Qin
Tang, Shuai
Lan, Guanghua
author_sort Jiang, He
collection PubMed
description WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The effects of concurrent human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection on mortality and patient attrition in those undergoing antiretroviral therapy continue to be a contested area of research. WHAT IS ADDED BY THIS REPORT? According to the propensity score-matched cohort, individuals with HIV/HCV co-infection exhibit an elevated risk of all-cause mortality [adjusted hazard ratio: 2.048, 95% confidence interval (CI): 1.526–2.749] and attrition (adjusted incidence rate ratio: 1.659, 95% CI: 1.4.8–1.961) compared to their counterparts who are mono-infected with HIV. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? The pressing need for tailored testing and follow-up protocols for individuals co-infected with HIV/HCV cannot be overstated.
format Online
Article
Text
id pubmed-10652092
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-106520922023-11-03 Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022 Jiang, He Zhu, Qiuying Huang, Jinghua Wu, Xiuling Li, Bo Liu, Xuanhua Meng, Qin Tang, Shuai Lan, Guanghua China CDC Wkly Preplanned Studies WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? The effects of concurrent human immunodeficiency virus (HIV)/hepatitis C virus (HCV) infection on mortality and patient attrition in those undergoing antiretroviral therapy continue to be a contested area of research. WHAT IS ADDED BY THIS REPORT? According to the propensity score-matched cohort, individuals with HIV/HCV co-infection exhibit an elevated risk of all-cause mortality [adjusted hazard ratio: 2.048, 95% confidence interval (CI): 1.526–2.749] and attrition (adjusted incidence rate ratio: 1.659, 95% CI: 1.4.8–1.961) compared to their counterparts who are mono-infected with HIV. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? The pressing need for tailored testing and follow-up protocols for individuals co-infected with HIV/HCV cannot be overstated. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023-11-03 /pmc/articles/PMC10652092/ /pubmed/38023393 http://dx.doi.org/10.46234/ccdcw2023.183 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Preplanned Studies
Jiang, He
Zhu, Qiuying
Huang, Jinghua
Wu, Xiuling
Li, Bo
Liu, Xuanhua
Meng, Qin
Tang, Shuai
Lan, Guanghua
Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022
title Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022
title_full Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022
title_fullStr Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022
title_full_unstemmed Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022
title_short Impact of HIV/HCV Co-Infection on Mortality and Attrition in Antiretroviral Therapy Among People with HIV — Guangxi Zhuang Autonomous Region, China, 2003–2022
title_sort impact of hiv/hcv co-infection on mortality and attrition in antiretroviral therapy among people with hiv — guangxi zhuang autonomous region, china, 2003–2022
topic Preplanned Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652092/
https://www.ncbi.nlm.nih.gov/pubmed/38023393
http://dx.doi.org/10.46234/ccdcw2023.183
work_keys_str_mv AT jianghe impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT zhuqiuying impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT huangjinghua impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT wuxiuling impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT libo impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT liuxuanhua impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT mengqin impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT tangshuai impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022
AT languanghua impactofhivhcvcoinfectiononmortalityandattritioninantiretroviraltherapyamongpeoplewithhivguangxizhuangautonomousregionchina20032022

Ejemplares similares